Secarna Pharmaceuticals Demonstrates Therapeutic Activity of LNAplus™ ASO Targeting NLRP3 in Autoinflammatory Diseases

Secarna Pharmaceuticals, a biopharmaceutical company specializing in antisense oligonucleotide (ASO) therapies, has published new preclinical data in The Journal of Immunology. The data demonstrates the potent therapeutic activity of their LNAplus(TM) ASO targeting NLRP3 in debilitating autoinflammatory diseases. NLRP3 is a central component of the inflammasome pathway, which is overactive in ma..